FDA Inspection 1199790 — Ultragenyx Pharmaceutical Inc.
The FDA completed an inspection of Ultragenyx Pharmaceutical Inc. on February 27, 2023 in Novato, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 27, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Novato, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)